Introduction to the types of cancers and indications that Axitinib (Inlida) can treat

Axitinib is an oral small molecule vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor that inhibits VEGFR-1< The signaling pathways of /span>, VEGFR-2 and VEGFR-3 block tumor angiogenesis, thereby inhibiting tumor growth and metastasis. Its targeted mechanism of action enables it to show potential efficacy in a variety of solid tumors, making it one of the important drugs in the field of targeted therapy.

Axitinib is most widely used in advanced or metastatic renal cell carcinoma (RCC), especially in patients who have received first-line anti-angiogenic therapy or immunotherapy. Clinical studies have shown that axitinib can significantly extend progression-free survival (PFS), improve patients' quality of life, and achieve tumor shrinkage in some cases. Due to its oral administration and controllable adverse reactions, it has become an important choice for second-line and subsequent treatment of advanced RCC.

In addition to renal cell carcinoma, axitinib has also been studied clinically in thyroid cancer (especially differentiated or medullary thyroid cancer), gastrointestinal tumors, non-small cell lung cancer (NSCLC) and other solid tumors. Some studies suggest that it can delay disease progression in VEGFR-dependent tumors and provide an auxiliary option for multi-line treatment options. However, these indications are still in the clinical trial or research stage, and specific applications need to be combined with guidelines and patient condition assessment.

In clinical use, axitinib should be formulated with an individualized plan based on the patient's disease type, tumor stage, previous treatment history, and liver and kidney function. Blood pressure, renal function and hemogram need to be monitored regularly during treatment, as hypertension, proteinuria or thrombocytopenia are common adverse reactions. Reasonable dose adjustment and standardized follow-up can improve the efficacy and safety, enable axitinib to exert a targeted anti-tumor effect in the treatment of various cancers, and provide patients with effective individualized treatment strategies.

Reference materials:https://www.drugs.com/